Seagen Inc
F:SGT
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
N/A
N/A
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
You don't have any saved screeners yet
Good day, and welcome to the Seattle Genetics Third Quarter 2019 Financial Results Conference Call. Today's call is being recorded.
At this time, I would like to turn the conference over to Peggy Pinkston, Vice President of Investor Relations. Ma'am, please go ahead.
Thank you, operator, and good afternoon, everyone. I'd like to welcome all of you to Seattle Genetics' Third Quarter 2019 Conference Call. With me today are Clay Siegall, President and Chief Executive Officer; Robin Taylor, Chief Commercial Officer; Todd Simpson, Chief Financial Officer; and Roger Dansey, Chief Medical Officer. Accompanying today's conference call are supporting slides, which are available on our website in the Investors section Events and Presentations page. Following our prepared remarks today, we'll open the line for questions. [Operator Instructions]
Today's conference call will include forward-looking statements regarding future events or the future financial and operating performance of the company such as those, among others, relating to the company's 2019 financial outlook, including anticipated 2019 ADCETRIS sales and future revenues, cost and expenses; and the company's anticipated timing to achieve potential future clinical and regulatory milestones, including data readouts, regulatory submissions and approvals.
Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Among the factors that may cause such a difference include the difficulty in forecasting sales, revenues and expenses, and the uncertainty associated with the pharmaceutical development and regulatory approval process.
More information about the risks and uncertainties faced by Seattle Genetics is contained under the caption Risk Factors, included in the company's periodic reports filed with the Securities and Exchange Commission, including the company's quarterly report on Form 10-Q for the quarter ended June 30, 2019.
And with that, I'll turn the call over to Clay.
Thanks, Peg, and good afternoon, everyone. Seattle Genetics has reached a transformational point in its history. We are poised to bring multiple targeted therapies to cancer patients in need. Our progress is evidenced by significant milestones across our oncology portfolio, including several in only the past few months.
First, ADCETRIS is a leading lymphoma brand that continues to grow with record revenues of $462 million year-to-date, up 34% in the first nine months of 2018. Under our collaboration with Takeda, ADCETRIS is on pace to exceed $1 billion in global sales in 2019. In addition, ADCETRIS remains the focus of a substantial clinical development program. At ASH in December, 10 abstracts will feature ADCETRIS in Hodgkin's and T-cell lymphomas including the four-year followup from the ECHELON-1 trial in frontline Hodgkin lymphoma.
Next, in our late-stage pipeline is enfortumab vedotin, or EV, which we're developing in collaboration with Astellas. During the quarter, we submitted the BLA for EV in previously treated metastatic urothelial cancer patients, and it was filed by the FDA with Priority Review with an action date of March 15, 2020. If approved, EV would be our second marketed product and expand our commercial portfolio into solid tumors.
Our EV U.S. sales force is in place, and we are looking forward to bringing this drug to patients in need. In parallel, we and Astellas are advancing a robust clinical development program for EV across the spectrum of urothelial cancer, including a planned Phase 3 trial in first-line metastatic patients. Roger will provide more detail about the impressive data presented at the European Society for Medical Oncology Conference and our development plans for EV.
Our next late-stage clinical program is tucatinib. Last week, we reported exciting results from our HER2CLIMB pivotal trial of tucatinib in metastatic HER2-positive breast cancer including patients with brain metastasis. The trial was a success and achieved its primary and two key secondary endpoints. Full results will be presented at the San Antonio Breast Cancer Symposium in December.
Data further supports tucatinib as a potential, best-in-class, HER2 tyrosine kinase inhibitor. Our team is already preparing the NDA, which we plan to submit to the FDA in the first quarter of 2020. This would put tucatinib in line to become our third marketed product. The HER2CLIMB data also supports our continued investment in the tucatinib clinical development program in earlier lines of HER2 positive breast cancer and in other solid tumors such as colon cancer.
Tisotumab vedotin, or TV, is a late-stage program we are developing in collaboration with Genmab. Our initial focus is in recurrent or metastatic cervical cancer. We expect to report topline data from the TV pivotal trial called innovaTV 204 in the first half of 2020.
Lastly, investing in our early-stage pipeline is a key part of our strategy for future growth. We are advancing multiple programs in ongoing clinical trials including ladiratuzumab vedotin or LV. We plan to report initial data at SABCS from an ongoing clinical trial of LV plus pembrolizumab in triple negative breast cancer patients. We will continue to advance innovative new product candidates into clinical trials, including ADCs and other targeted therapies with several INDs planned in 2020.
At this point, I'll turn the call over to Robin to discuss our commercial activities, then Todd will comment on our financial results and 2019 guidance. After that, Roger will discuss our clinical development activities. Robin?
Thanks, Clay. ADCETRIS net sales in the U.S. and Canada were $167.6 million in the third quarter, an increase of 32% compared to the same quarter in 2018 at an increase of 5% over the second quarter of 2019. Continuing growth in Q3 reflected an increase in the overall share of frontline PTCL patients treated with ADCETRIS and sustained share in frontline Hodgkin's lymphoma.
The PTCL growth was highest among the newly diagnosed ALCL patients with a significant majority receiving ADCETRIS. Our sales organization is focused on continuing to promote ADCETRIS under its broad label that now includes six indications. They are also emphasizing the three-year PFS data from the ECHELON-1 trial in order to continue to shift adoption for advanced stage Hodgkin lymphoma patients. The data showed there was extended followup. The PFS benefit was maintained with ADCETRIS+ AVD. We are narrowing our 2019 ADCETRIS sales guidance to $625 million to $640 million.
Now, I would like to transition to enfortumab vedotin. We are encouraged by the positive reaction from investigators and key opinion leaders to the EV-201 data that was presented at ASCO. There is significant need in metastatic urothelial cancer post platinum chemotherapy and PD-1, or PD-L1 therapy and we look forward to providing a new option for patients.
We are actively preparing for the potential approval and commercial launch of EV. EV sales team is fully onboard and in the final phase of training to ensure that we are ready to launch upon FDA approval. Our sales organization was hired from 18 different companies in addition to Seattle Genetics and has an average of 14 years of oncology experience.
Our team is also actively engaging with key players to provide them with information and help them plan and budget future coverage and/or reimbursement decisions related to EV. We are working in close collaboration with our partner Astellas to ensure the joint commercial team is launch ready.
Moving on to tucatinib, our commercial team is excited by the results from HER2CLIMB. We have been preparing launch plans in anticipation of the data that we announced last week. Hiring of the U.S. sales leadership team has already been initiated with a focus on deep expertise in the breast cancer space. I am confident that we will have a highly experienced tucatinib sales force in place in advance of approval.
In summary, ADCETRIS is the mainstay of our business, and we continue to focus on expanding our newer indications of frontline Hodgkin lymphoma and PTCL. We look forward to potential approvals and launches of EV and tucatinib and making a huge difference in the lives of cancer patients.
Now, I'll turn over the call to Todd.
Great, thanks Robin and thanks everyone for joining us on the call this afternoon. Today, I'll summarize our financial results for the third quarter and year-to-date and provide a few updates to our financial outlook for the year. Total revenues were $213 million in the third quarter of 2019 and $627 million for the year-to-date. This included record ADCETRIS net sales in the U.S. and Canada of $168 million in the third quarter and $462 million for the year-to-date.
Royalty revenues in the third quarter of this year increased to $27 million compared to $23 million in the third quarter of 2018. For the first nine months of 2019, royalty revenues were $66 million compared to $59 million for the same period last year. Royalty revenues primarily reflected ADCETRIS sales by Takeda and to a lesser extent sales of Polivy under our collaboration with Roche.
Collaboration revenues were $18 million in the third quarter and $99 million for the first nine months of 2019. This included the earned portion of $43 million in milestones achieved earlier this year most notably triggered by Takeda's approval and ADCETRIS in frontline Hodgkin lymphoma and the recent approval of Polivy.
R&D expenses were $196 million in the third quarter of 2019 and $518 million for the year-to-date. Growth over 2018 reflects higher investment across our pipeline primarily on our late-stage programs tucatinib, EV and TV, as well as the upfront cost of our preclinical asset that we acquired in the third quarter. SG&A expenses were $96 million in the third quarter of 2019 and $259 million in the first nine months of the year. These are both increases over 2018 and reflect commercial efforts to support ADCETRIS in frontline Hodgkin lymphoma and PTCL launch preparation activities for EV and costs related to supporting our other late-stage pipeline programs.
We ended the third quarter with $870 million in cash and investments which includes net proceeds of $549 million from our July common stock offering. In addition, we hold approximately $102 million in Immunomedics common stock. These shares are mark-to-market and contributed to a small investment loss for the quarter and year-to-date this year, but created some variability in results in 2018.
Lastly, I want to highlight four upbeats to our financial outlook. On revenues we are narrowing our ADCETRIS net sales guidance to a range of $625 million to $640 million. In addition, based on the strong sales by Takeda we are increasing our expectations for royalty revenues to a range of $90 million to $95 million.
On expenses, we are updating our R&D expense guidance to a range of $690 million to $715 million. This reflects the technology acquisition that I referred to earlier as well as development activities for EV and tucatinib. And lastly, following the positive HER2CLIMB results last week, we expect to initiate several launch preparation activities this year for tucatinib. As a result, we are increasing our SG&A expense guidance to a range of $355 million to $370 million. We plan to provide our 2020 financial guidance on our next quarter call.
Now I'll turn the call over to Roger.
Thanks, Todd and good afternoon everyone. The past few months have been remarkably productive. This afternoon, I will recap key outcomes and activities in our late-stage programs and highlight our development plans going forward to maximize the potential of these programs for patients in need.
I'll begin with enfortumab vedotin. Positive data from the clinical EV-201 trial in metastatic urothelial cancer patients who received prior platinum chemotherapy and PD-1/PD-L1 treatment were presented at ASCO and published in the Journal of Clinical Oncology. The data supported our Biologics License Application that we had submitted to the FDA in July and was accepted for filing by the FDA in September with a PDUFA date of March 15, 2020. We and our partners Astellas are actually engaged with the FDA in support of the application.
As a reminder, EV previously received Breakthrough Therapy designation from the FDA in this patient population. Beyond our initial registration pathway, our development plans are evaluating EV in the first line metastatic setting as well as in earlier stages of the disease. This is supported by initial results from the Phase 1 EV-103 trial presented at ESMO in September, where we reported data from 45 metastatic urothelial cancer patients who were previously untreated and were ineligible for cisplatin based chemotherapy.
Cisplatin ineligible patients typically receive a carboplatin regimen with is associated with a response rate of approximately 36%. The study met outcomes for safety and in addition, among those patients who received a combination of EV and pembrolizumab, the objective response rate was 71% including a 13% complete response rate. A total of 93% of patients had reduction in tumor volume. The combination of EV and pembrolizumab showed a manageable safety and tolerability profile.
Importantly, we observed responses regardless of PDL-1 expression. Treatment related adverse events of clinical interest that were grade 3 or greater were rash, hyperglycemia, and peripheral neuropathy. These were expected events and a range with similar were observed with enfortumab vedotin mono therapy. 11% of patients had treatment related immune mediated adverse events of clinical interest greater than or equal to grade 3 that required the use of systemic steroids.
This was consistent with the safety profile observed with pembrolizumab mono therapy which does not appear to worsen with the addition of EV. Based on these data, we are proposing to conduct a frontline randomized Phase 3 trial. We will provide additional specifics about our Phase 3 plans in the coming months.
EV plus pembrolizumab represents second encouraging data set that has been generated from the combination of vedotin based ADC as a checkpoints inhibitor. We have previously shown promising data from the combination of ADCETRIS and nivolumab in several lymphoma settings. We believe in the potential of combining our vedotin based ADCs with immune checkpoints inhibitors and we are evaluating similar cross combinations across our ADC frontline.
The EV-103 trial is ongoing in first line metastatic urothelial cancer patients to evaluate the combination of EV and platinum chemotherapy as well as the triplet of EV, pembrolizumab and chemotherapy. In addition, we recently expanded the trial to evaluate EV monotherapy and the combination of EV and pembrolizumab in patients with muscle invasive urothelial cancer who are cisplatin ineligible.
Approximately 20% of urothelial cancer patients are diagnosed with muscle invasive disease which is not [indiscernible]. There is a significant unmet need for new therapies for these patients. Lastly, the activity of EV in the urothelial cancers suggests it may have application in other Nectin-4 expressing latencies. To that end, we have planned to start a single finding trial in other solid tumors in the near future.
I'll move on now to tucatinib, our own tyrosine kinase inhibitor that targets HER2. Last week we reported positive topline results from the randomized, double blind, pivotal trial called HER2CLIMB. The trial was conducted in 612 heavily pretreated HER2-positive metastatic breast cancer patients, including 47% who were known to have brain metastases at the study entry. The patients received either tucatinib in combination with trastuzumab and capecitabine or trastuzumab and capecitabine alone.
We reported a statistically significant and clinically meaningful outcome on the primary end two key secondary endpoints. The data showed that the tucatinib regimen reduced the risk of disease progression by approximately half and by a greater amount in the patients with brain metastases. Most importantly, tucatinib also reduced the risk of death by a third in the overall population. Tucatinib in combination with trastuzumab and capecitabine was generally well tolerated with a manageable safety profile. The results from HER2CLIMB are scheduled for oral presentation at SABCS on December 11, 2019 and we expect to submit a new drug application to the FDA in the first quarter of 2020.
Next, I'll turn to ADCETRIS which we are evaluating in several new trials for potential registration or to informed clinical practice. As previously stated, we are enrolling patients who are being retreated with ADCETRIS in Hodgkin and T-cell lymphoma who progress after prior response including those who received ADCETRIS in the frontline setting. We are also conducting a trial of ADCETRIS in frontline Hodgkin lymphoma and PTCL patients who are unfit for combination chemotherapy.
In addition to these studies, we recently expanded an ongoing Phase 2 trial to evaluate ADCETRIS in a novel combination of nivolumab, Adriamycin and dacarbazine in newly diagnosed, advanced Hodgkin lymphoma patients. This regimen excludes vinblastine, which is part of the approved ADCETRIS plus AVD regimen and adds nivolumab. Vinblastine is known to cause neuropathy and ADCETRIS in combination with nivolumab has produced promising data in several clinical trials.
Combining the two most active agents in Hodgkin lymphoma, ADCETRIS and the PD-1 inhibitor, in a frontline regimen, has the potential to improve efficacy and reduce toxicity. The trial reflects our long-term strategy to improve outcomes for Hodgkin lymphoma patients with ADCETRIS based regimens.
Another ADCETRIS opportunity we are exploring is its use in the treatment of diffuse large B-cell lymphoma. We will keep you posted as our plans progress. We also have a number of important presentations at ASH and look forward to continuing to expand the ADCETRIS data set in hematologic malignancies.
Now, I'll turn the call back over to Clay.
Thanks Roger. Before we open the line for your question, I want to recap our key upcoming activities across our oncology portfolio. They include, first, continue to establish ADCETRIS as the standard of care in frontline Hodgkin lymphoma and frontline PTCL and initiating additional clinical trials.
Second, working with FDA on our EV submission in collaboration with Astellas towards the March 2020 PDUFA date, initiating a Phase 3 trial in frontline urothelial cancer and expanding the EV development program with new trials.
Third, reporting to tucatinib HER2CLIMB data at SABCS, submitting an NDA to the FDA in the first quarter of 2020, and advancing a randomized trial in combination with T-DM1, and reporting topline results from TV pivotal trial in cervical cancer in the first half of next year.
We aim to continue a positive momentum through 2019 and into 2020 as we strive to bring important new drugs to cancer patients.
At this point, we'll open the line for Q&A. Operator, please open the call for questions.
Thank you, sir. [Operator Instructions] And our first question will come from Michael Schmidt with Guggenheim.
Thanks for taking my question. So, I've actually had a pipeline question on ladiratuzumab. As you mentioned rightfully so, I think a lot of excitement around combining your ADCs with PD-1 inhibitors, and you did mention the upcoming presentation of the Keytruda combination study at SABCS. I was just wondering if you could help us little bit more with what investor expectation should be with respect to this update from LV plus pembro that's come later this year?
Michael, thank you for the question. So, we are very interested in the LV-1 ADC. It is an interesting molecule. It’s certainly active. We’ve shown that and presented that it has single agent activity, and we are continuing to evaluate it as a monotherapy and also in combination with pembro. We are not yet ready to go forward and announce registrational or Phase 3 trials, but we are continuing to develop it and trying to maximize dose schedule monotherapy combination with pembro, and we're very excited about that.
Clearly SABCS will be, from a Seattle Genetics standpoint, a big show on tucatinib because we have a lot to discuss here, but LIV-1 is also important to us, and additionally I may point out that the Basket trials in a variety of different tumor types that have LIV-1 expression has recently opened. So that's something we're working on as well.
Great, thanks. And then maybe a follow-up. So, you mentioned the upcoming trial results for the TV study in cervical cancer from the innovaTV 204 trial. Can you just remind us of sort of expectations for what the clinical barriers are here in terms of efficacy for approvability?
There is a lot there and maybe I'll give you a few comments, but Roger can also follow up. And if you look at relapsed cervical cancer, it's a grim prognosis. No one survives this. This is bad, and despite GARDASILand vaccines, not everyone gets vaccine across the globe and in the U.S., and so there is still unfortunately a need for therapies for relapsed cervical cancer.
And if you look at perhaps the most recent approval in cervical cancer, it was pembro in PD-1 high-expressers with a 14%, that's 14% response rate, but they were durable responses. And if you look at chemotherapy that has been used in a lot of publications, there are, I would say the range is probably somewhere between 8% and maybe 16%, 17% response rate sometimes with durations that are tiny measured in two months of duration whereas with a checkpoint you can get a year or so of duration which is likely why it got approval even with the de minimis response rate because it had duration.
So, I think those maybe could help you give you some landmarks of what's out there, and clearly we want to do well by patients and have the best response we can have with single agent, look at this in future in combination. Roger, do you have any color you want to add beyond that?
No, Clay I agree with your comments that the bar is set by historical precedent and we need to wait for the TV results to see how they match up.
Great, thanks. There is lots to talk about obviously, but congrats on all the pipeline progress in the quarter. I'll hop back in the queue.
Thanks.
Thank you. Our next question comes from Kennen MacKay with RBC Capital Markets.
Hi, thanks so much for taking the question. Congrats on the quarter and the narrowed and slightly raised guidance. Maybe a quick commercial question first. I hoped for a little bit more color on the growth of ADCETRIS in frontline PTCLs and the higher growth in CTCLs where it seems like two factors are at play. All of those patients are CD30 positive and I think the NCCN guidelines there are maybe a little bit more generous versus other PTCLs.
So, I was wondering, of those two drivers, which had been the bigger impediment to use outside of PTCL or sort of lack of broad CD30 testing there or just lack of supportive data, and really what can be done about that to increase utility outside of PTCLs? And then I have one quick follow-up.
So, you know, there has been a lot of work done. I am looking at CD30 expression in both CTCL and in PTCL. And if you asked scientifically, are there patients with PTCL and CTCL that are absolutely negative for CD30? I could not with a clear conscience say that there are patients that are truly negative. What I could tell you is, there are some patients that have low scores on histology when looking at a single nodule, but if you look at other nodules they could be high.
Keep in mind. CD30 is an activation antigen. And if you take some tissues that are low or in background with histology and you do other types of techniques to look at expression, you can see CD30 expression there. So, to me it's not totally -- is our CTCL and PTCL CD30 positive or negative. It's more of a, what the rate, what the expression level is and some really in the background of histology, which is kind of a blunt tool although readily used across different cancer centers. So it's an easy tool to use.
So, having said that, you're asking about what could we do about that? How can we grow? And there have been trials done and evaluated -- for instance in CTCL that were presented not that long ago, showing that you have CD30 positive and in CD30, I will call histology negative. And then the doctors treated both populations and had really good responses in both. So, it was a little bit higher in the CD30 positive than the CD30 histology negative, but they certainly weren’t CD30 negative.
And so, I think there a lot of things that we could do as we get out there and just product is in the field longer and study this and Roger, you know a lot about expression of this. And is that something that you want to comment on?
Yes, no, I think and Clay has made the point that there is a dynamic nature to this expression, and there is a sampling variability and we have data, not just in CTCL, but in other diseases as well with CD30 expression. I'm going to extend it to Mark for responses where we have parents CD30 negativity where we see response.
From a testing perspective obviously pathologists are an important part of this and getting the pathologist to understand the importance now of CD30 testing in PTCL because it is a therapeutic that can make a difference. It is something that we are obviously focused on and interested in trying to improve adoption of scoring and the appropriate reporting of pathology.
Great, thank you very much. And then I had one quick pipeline follow up. I'm up here in Boston at the AACR-NCI-EORTC triple conference and some of the data on the next generation good [indiscernible] linkers and [indiscernible] payloads was presented up here maybe enabling higher payload delivery per ADC. Can you maybe help us understand the utility of these technologies? And I think this is getting used on one of your next generation ADCs SGN 228A which is in Phase 1. If I am right on that could you maybe help us understand when we might see some of that initial data on what to look for in that data? Thank you very much and congrats again.
Thanks, Kennen. So thank you for the introduction to talk about stuff that's part of our growing technology and our leadership in ADCs. So we are really excited about our newest ADC in clinical trials that we call 228A and targets CD228 or what's referred to as PA97 and this is expressed on a variety of solid tumors. And we have also not only just used this target, but we have used that new confirmation in ADC that utilizes pet groups, utilizes and implode, you may be aware that with ADCETRIS and with LV we utilized approximately 4 drugs per antibody molecule and with our newest technology with 228 we're using 8 drugs per antibody molecule. But it has a completely different linker and in a completely different stabilization agent and we've been working on this and it's in clinic now and it's an exciting prospect for us.
One of the commitments that we've made is after we became the industry leader in ADC is to stay there and that's to continue investing in our technology and continue to make drugs that are more potent but also safer and try to work on our liquid systems to make them more specific for the tumor. And so, this is one example where we are very hopeful with our technology and we are investing in new ADCs.
But as you will see going forward, we have a couple of new technologies to build on what we already have is the leadership positions. And I think that the future will be a good one for ADCs not only at Seattle Genetics, but in other companies as other companies are making advances and really helping patients.
Okay, thank you. Our next question comes from Salveen Richter with Goldman Sachs.
Thanks. Could you just comment on the next steps for tucatinib in colorectal cancer and perhaps plans to look at other indications such as gastric or the frequency of HER2 overexpression is much higher?
Thank you very much for the question. Roger, can you talk a little bit about maybe on data and what we're doing next and then also touch on other diseases.
Right, so thanks for the question. And obviously the HER2CLIMB results, which are really in our view remarkable, does point to the potential best-in-class nature of tucatinib. And so we are interested in, since we’re creating a program around tucatinib which will include expanding into other areas of breast cancer and Clay has already mentioned the TDM-1 trial, which is an earlier stage of metastatic disease, we have a neoadjuvant efforts through ICE by two and we are looking at other areas as well.
With regard to HER2 expressing tumors that are outside of breast cancer, we did have very exciting data, a small data set but very exciting at ESMO with the combination of trastuzumab/tucatinib with a response rate that's north of 50% and looked pretty durable. So we're excited about taking it on, so much so that that was an investigator initiated trial, which we've taken over. We now essentially only IND and the trial is now Seattle Genetics open-sponsored trial.
And we plan to continue to evaluate third line colorectal cancer HER2 positive in a broader patient population utilizing the MOUNTAINEER Trial. And that obviously if that data is reproducible which we think it will be, that's an area of potential seeking potential registration outcomes. And in earlier lines of colorectal cancer even though the frequency is in the sort of 2% to 5% range, nevertheless, it's an important unmet need and it's a large addressable population. And we are working on thinking about what we could do earlier.
With regard to gastric, exactly as you say, this is another opportunity and we already have thought through internally, what a development plan could look like. We're not ready to share that information at this point, but we are definitely interested in gastric and potentially other HER2 expressing tumors as well.
And a follow-up if I may, at this point how much is ECHELON a driver with ADCETRIS revenue growth versus PTCL?
I'll turn it over to Robin in a moment, but the general answer is, we really don't split them up and both of them are a very important to us. Robin, you want to give a little color?
Sure ECHELON is certainly one of the key revenue growth areas for ADCETRIS and I think there is certainly room to grow with Hodgkin lymphoma. We've seen good uptake both PTCL and Hodgkin lymphoma. But Hodgkin lymphoma is really facing a much more entrenched usage chemotherapy. The three-year PFS data that we presented has really helped us get traction in terms of physicians understanding the benefit of ADCETRIS and we will have four-year follow-up data at ASH. I think as the data matures with ECHELON-1 what one could see is that there is, we've seen that continued benefit from the three-year PFS data.
The more we can show that there is an interim benefit. I think the more that we are going to be able to convert physicians to understanding the benefit of ADCETRIS. In terms of the relative contribution, as Clay said, we don't split those up, but I believe that Hodgkin lymphoma is continuing to be an important driver for us. We've seen obviously rapid uptake with PTCL as well and I think that's been very encouraging.
Thank you. Our next question will come from Gena Wang with Barclays.
Thank you for taking my questions and the first one also regarding the commercial question, so wondering how's the first line PTCL and the Hodgkin lymphoma the growth trajectory or growth rate in this quarter compared to the last quarter?
So, we don't report the specific growth of the disease types. As a whole, we've had a lot of growth year-over-year and quarter-over-quarter, we grew a little about 5%. And so that is – it's a strong growth rate within what we have there for guidance. And we're excited about that and we expect that ADCETRIS over time year-to-year will continue to grow as a brand as we make more progress there, but the specifics of PTCL for instance as you asked is not something we present.
What I will say is that would PTCL we had OS from our first data set. So it is a less challenging discussion with doctors when you go out with OS data. Whereas with Hodgkin lymphoma it was contemplated to be – to take a number of years to get there because you need a certain amount of events to hit statistical volumes, so we are not there and it is important for us to follow the protocol as it said and as it's written and try to get to those events.
But in the meantime, the gold standard is five years and docs look at that with Hodgkin lymphoma. Our additional data, which we published showed two-year worth of data and some doctors and it was great data some doctors converted and some didn't. And then last year we put out our three years data and we had a nice bump in our revenues and more docs took it on and the data got actually better, it wasn't just continuation of two to three years it look better.
And now this year, we're going to show at ASH coming up in a couple of months, we're going to show four-year data and then next year, presumably at ASH, but it's way too early to speculate we'll show the five-year gold standard data. And I think that that will go a long way to addressing any questions without even having OS data. So we're really excited to continue to age, the data and go forward.
Right and then just quick follow up, quick question regarding the EV-103 fleet. And so, you did mention that you plan to start randomized the Phase 3 trial in first-line. Just wondering any additional color you can provide and giving those individual 130 data reported at ASCO? And will you be thinking about triplet versus doublet or it will be any one or three plus pembro versus pembro alone?
No, we have not yet spelled out the exact trial and that's something as soon as we start to trial we will spell it out, that's been our history that it's not appropriate to state the exact trial till it starts. So stay tuned we will be doing that but Roger, perhaps you can give some color on your thoughts on and bigger and the kind of approaches we could take to go toward approval and the importance of it.
Sure, thanks Clay. But as you can see the EV-103 trial offers you a roadmap as to how we're thinking about what possible combinations we can use and as Clay said, we haven't disclosed those, but you can get a sense of the data generation that we will need to support the Phase 3 frontline trial. With regard to, we got the positive trial the OS didn't quite make it obviously from a, from an efficacy perspective it is, although it's hard to cross compare we are encouraged by our EV pembro data, which has been a response rate of 70%, which is an unusual outcome in this disease.
And again, cross trial comparisons have limits for sure. But the response rates that were shown with the trastuzumab together with chemotherapy would suggest that at this point anyway. What our plans to proceed into a frontline trial would suggest that we have a good shot to potentially improving the outcomes further.
All right, thank you.
Our next question comes from Andrew Berens with SVB Leerink.
Good afternoon and thanks for taking the questions. This one is primarily for Roger, one of the buzzes that came out of the EV presentation in Barcelona was potential synergies between the then checkpoint. And I think it's one of the things, a lot of investors are also thinking about in regards to how the value of the platform. Do you guys have any additional color for us regarding what could be driving potential synergies and is there anything about the payload or the linker or they are differentiated in regard to other ADC approaches?
Sure Roger.
Sure, thanks for the question and so it's the Holy Grail those drug developments just to be able to put two drugs together and have a better outcome then in the individual drugs alone. And certainly that response rate is high proof of synergy is a very different thing, which requires a high level of scientific vigor. And what I can say, is that from a mechanistic perspective, you think about what an [indiscernible] years so it’s essentially a targeted therapy.
So delivering a payload to a group of tumor cells inducing in those tumor cells things like immunogenic cell death, replicas of stress, such that the tumor microenvironment may become favorable for an inflammatory response and may in fact be amenable then to an immune response that would be assisted by taking the brakes off at immune response by getting a PD-1 or PD-1 inhibitor. And in the sense of chemotherapy may be much more permissive in terms of what other cells could potentially damage, one could speculate that that limited delivery of a cytotoxic payload, just the tumor cells may keep the microenvironment more intact. That's one possibility.
With regard to the actual data, in terms of what does - could 71% represent synergy? What is interesting is, if you look at the data you can see that there is a response regardless of PD-L1 expression, which is encouraging. We don't have EV monotherapy data at this point to sort of make the comparison. So it's very hard from a pure numbers perspective to say, this is what you'd expect with pembro, and this is what you could expect from EV. That regardless of whether it's synergy or not, the clinical data are pretty compelling and it's certainly compelling us to move forward with the development program.
Okay. Is there anything about Vedotin specifically or your Linker [ph] technology that could make it hard for another ADC to have similar effects?
You know Andy, you're asking a really good question. And there's a lot of work going on in our research effort that I do not or research group I should say, that do not, are not ready for a full discussion. And we're - what we're doing is in general, is we're evaluating all the different types of payloads and their impact on immunogenic cell death. And I can tell you that they're not all the same, but don’t work really well there. And I don't want to say more than that at this point. And at some point in the future, we'll put out our research data at appropriate conference like an AACR type conference, but we're really excited with our choice of Vedotin and how they work well with immuno-oncology agents like PD-1s.
Thank you. Our next question will come from Andy Hsieh with William Blair.
Great. Thanks for taking my questions and congratulations on the quarter. So it's encouraging to see that Seattle is really hoping to expand the front line treatment paradigm for Hodgkin lymphoma and also NTCL [ph]. So just curious, you know, these Phase 3 trials usually take anywhere from three to five years to run. Anything you guys learned from the ECHELON programs in terms of potential surrogate endpoint to kind of shorten these trials?
It's a good question. I think especially in the Hodgkin lymphoma space there is the stage 1 and 2 that we do. We do not yet have approval for example. And despite that, there is a lot of good data that's been presented, but albeit they're relatively small trials and they're not approval trials, but the data is strong. And I think that, when you look at work that's going on, whether it's in Europe with consortiums or cooperative groups in the U.S. or corporate studies, I think that there is a building momentum for using ADCETRIS in a lot of lines of Hodgkin lymphoma. But we have to continue really powering through trials and try to look at some novel endpoints such that they don't take very long. And I think that that is something that is up for discussion with regulators. I can't give you any details on that. Roger, is there anything else you want to say based on what we can.
Yes. I think, Clay is right there. It's not just corporate trials that drive these, what can be fairly long sometimes running. There are cooperative groups and so on, which are important entities including trial execution. We are interested in what we talked about today was a single finding study to see if we could in a single arm trial show what an ADCETRIS, nivolumab, Adriamycin and dacarbazine combination could look like in frontline advanced Hodgkin lymphoma. And we think if that data is compelling enough, that could then be the Genesis for yet more work on the bio cells or by others to see. Because the ultimate goal is to cure as many people as we can. And that's, I think, what our focus is on in terms of developing new treatments for Hodgkin lymphoma, new combinations.
And a follow up if I can, so in terms of DLBCL Clay, I think in 2015, ASCO when the company decided to forego the frontline opportunity, I'm just wondering what changed there? I think you mentioned about just the markets were pretty crowded, and given kind of failures in the frontline setting one with Revlimid, one with Imbruvica were those kinds of the Genesis behind the rationale to look at potentially frontline DLBCL again?
So first of all, we are in NCCN with DLBCL and so we hear back from doctors, who utilize it and that's an important thing to try to understand what's going on in the world. And we've figured that out over the last couple of years and have been able to talk to docs and been able to understand the benefit that ADCETRIS has in DLBCL. The landscape has changed and not necessarily, we had big victories as you say. And there are other specifics that we have in mind, but we have not announced a specific trial yet. But it's coming and we're excited with it as something, you know, that we need to obviously work through regulators and with the team here at Seattle Genetics and we're trying to go forward and see if we can get another label in DLBCL, so stay tuned on that.
Great. Thanks for taking all my questions.
Thank you. Our next question will come from Shanshan Xu with Berenberg Capital Markets.
Hi. Thank you for taking my question. A few quick ones from me. So this year at ASH, I believe you will have the four-year update for ECHELON-1 on the PFS front. Can you please update with us when should we expect the OS updates for ECHELON-1?
Yes, like I said earlier in the call, OS has a preset, a target number for events. And at that point is when we open up the trial and we have not hit that. It has always been contemplated to be quite a number of years. So we're just not there and it would be inappropriate for me to try to tell you when I think it's going to be, since it's a hard prediction.
In the meantime, we are getting PFS data, and our PFS data is aging from two years to three years to four years presentation in a couple of months at ASH, we're excited to do that. And then next year hitting that gold standard of five years PFS. And as we get closer to the five-year PFS data time point, doctors ask about the OS less, because if you're at five-year PFS and your lines are pretty flat in the Kaplan-Meier plots, that signifies really what the doctors need to know. So, while we are going and planning on getting OS I think that five year TFS is going to be very significant as well.
No problem. My next one is that, given the strength of data from HER2CLIMB and the fact that you're already initiated HER2CLIMB [indiscernible] TDM-1, we actually look forward to including this market opportunity in our model. So how should we think about the size of the indicated patient population for tucatinib and TDM-1 combination considering the dynamic in the treatment arena for HER2 positive breast cancer patients?
Right. Well, you know, we haven't really come out yet at this point and talked about the size of the population. I mean, it is a little premature for us. We just came out with our data to start talking about what we think size of population is, and which leads right into a marketplace discussion, which leads into a pricing discussion. We have done a lot of work on this. We have been doing a lot of work. We're intending for HER2CLIMB to be not just a U.S. product, but a global product. I mean, we have a randomized study and a great dataset. We're really looking forward to presenting that dataset at San Antonio. And, so I think that the market opportunity is substantive and you'll be hearing more from us on that in the future.
Thank you. Our next question will come from Silvan Tuerkcan with Oppenheimer.
Thank you for taking my questions and congrats on all the progress this quarter. It's very promising that you think about moving into muscle invasive bladder cancer with EV, what types of data have you seen before to inform the utility of EV in this setting?
Thanks for the question. I will turn it over to Roger to give you his thoughts on muscle invasive bladder cancer, which is a really big opportunity and an unmet medical need opportunity. But we have not, we have recently opened a cohort of patients, so we're just now treating our first patients in muscle invasive. So if you're asking, what is our clinical data, we are assembling our first clinical data. If you're asking about preclinical, about why we are looking at this, we have looked at expression of Nectin-4 in the pre-metastatic stage and certainly it's expressed strongly there as well.
And there's been a bunch of preclinical work that have been done to show that we think that this could be very effective in not only muscle invasive but even earlier stage in that non-muscle invasive. So in all stages of bladder cancer, which is a very substantial sized market with about 80,000 incidents in just the U.S. each year for those three types of cancers, the metastatic, the muscle-invasive and the non-muscle invasive. So, a lot of preclinical work, a substantial amount of clinical work in metastatic, both the single agent and combination and now we're treating patients in muscle-invasive. Roger, is there any other details?
Yes, I think EV is obviously active in metastatic disease. And so, one could, it's not a difficult step to take to expect that it may have meaningful activity in Nectin-4 expressing non-metastatic disease. And so I think that's where we are. We obviously as close as we need to generate the data, so we can see exactly what the effect of EV monotherapy is and also look at the combination and as you know, a landscape for muscle-invasive bladder cancer because there is a meaningful unmet need is busy right now, there are lots of trials that are running.
And so understanding, what a reg pass forward could look like, we already have evidence. So we have good examples ahead of us. And so, if we are able to take EV into a randomized trial, essentially, a population splits into cisplatin-ineligible and cisplatin-eligible and the reason why it is cisplatin-eligible versus ineligible because cisplatin is the only drug that is shown versus cisplatin combination is the only combination that is shown to actually have benefits in the muscle-invasive space. And so you can see clinical trial designs, compartmentalize those two populations.
And we would be interested obviously, in both. We have generated data with EV pembro in the cisplatin ineligible metastatic population. And we do have that first piece of information and just stay tuned and we're working on moving EV-4 into these earlier lines of bladder cancer.
Great, thank you so much. And a quick follow-up if I may. I'm also encouraged that you already expanded tucatinib. What made you initiate tucatinib plus Kadcyla and was anything promising that you've already seen there to plant data set or is it just a commercial mission?
Please keep in mind that there was a study that had been done, an early study that was single arm, not randomized, but it combined tucatinib and Kadcyla and the data had been presented at a conference and they were very strong. So we do have the early data.
And to us together with the early data, and the outstanding HER2CLIMB data that you'll see in San Antonio, it makes sense to go earlier in line and invest in it. And this time, it's a randomized study. And so we don't need to do another single arm study that's been done and the safety and efficacy or the risk benefit that some docs call it, looked pretty darn good. But it was a single arm study. So we are investing in a randomized study that is up and running.
Great. Thank you so much for taking my questions.
Thank you. Our last question in the queue comes from Tazeen Ahmad with Bank of America.
Hi guys, thanks so much for taking my questions. Maybe Todd a couple on the financials. So as you guys diversify out away from ADCETRIS and a lot of the key studies for ADCETRIS have read out. You are putting more money now into the rest of the pipeline, whether it be EV or tucatinib or TV. Can you give us a sense about the waiting of expenses for modeling purposes for EV versus the rest of the program on a go forward basis? Should we assume that EV is the bulk of expenses just based on what you said or do you think that, it will be more equal spread across all of your pipeline products? Thanks.
Yes, so great question. I don't know that I can give you specifics on exactly how it spreads, but historically ADCETRIS has been the prominent driver of our expenses. We've now got six labels. We've run a number of very large clinical trials and while we're continuing to do additional work some of which you heard on the call today. It's becoming a probably a lower overall percentage of our investment in R&D, what is now really starting to come forward are investments in programs like ECD, where as you heard today, we've got a very expansive development program for that compound as well as tucatinib.
I think HER2CLIMB data to us turns this into a program, not a clinical trial. You've heard a little bit about our work that's already starting in combination with Kadcyla in lines of therapy before the HER2CLIMB setting. And then certainly we're looking at things like colorectal cancer where the data that we presented as well were quite encouraging.
So, you know, I think maybe to get back to your question, I think you'll see a growing share of expense hitting programs like enfortumab and tucatinib. ADCETRIS will continue to be substantial, but probably becoming a smaller contributor to the overall pie. And then, we'll obviously look to see what else comes out of the pipeline. We've got TV in a pivotal study in a very broad portfolio of earlier stage assets that we just talked a little bit about today.
Okay. Thank you. Our next question comes from Chad Messer with Needham & Co.
Great, thanks for taking my question and congrats on all the recent progress. First real quick, is there any words you can say about the preclinical assets that Todd referred to in prepared remarks, maybe you can just a rough idea, what the spend on that was?
I can tell you not from a financial standpoint that we do a lot of different deals and we bring in technology, we bring in preclinical assets. This is has happened like almost every year we do, small different deals and some of them work out really well and some of them they are just in our research front, and Todd, you could talk a little about why it was in – why you mentioned it.
Yes, sure. So, not that it was a huge deal, but it was the principle driver of why we increased our R&D guidance just a bit. So, I can't give them the numbers out, but that was the main contributor. And as Clay mentioned, it's a really interesting preclinical asset that we think could become clinical assets relatively soon. So that's what got us excited about it.
Great. Yes, that's very helpful. And then just for a follow up, let me - couple of questions here, but they're all very related, if you can indulge me. I wanted to go back to TV. Clay, you mentioned, how terrible relapsed cervical cancer is and that not everybody gets vaccinated, so it's still a problem. What is your view of the kind of opportunity in relapsed cervical cancer, but also for TV, I know you're looking at a whole bunch of other cancers that express tissue factor. So your thoughts on the opportunity for a tissue factor targeting therapy more broadly, and then tissue factor itself - can you just remind you, is that sort of as sparingly expressed across tumor types? You know, say like a CD30 is, or is it a little bit more uniform? Thanks for taking my questions.
Sure. So, first of all on TV, we have expanded past just cervical for sure. We have a trial that's listed on clintrial.gov that's in ovarian cancer and we have a Basket study we're working on in other types of cancers. So, stay tuned for us to report in the future when we have enough substantive data at appropriate peer-reviewed conferences, like we always do on the data outside of cervical that we're working on.
So is a lot of interest in it and you asked about the expression of tissue factor and that's something that is expressed broadly on solid tumors at very high density. It is not really a huge target, so I wouldn't expect us to go and do a lot of lymphoma, leukemia myeloma type work with it, rather it's more on the solid tumors that you would expect, the big solid tumors and the expression on cervical and things like ovarian very high. So, really good targets and important diseases that need additional therapies that have unmet need for a lot of patients. So we're really excited about our partnership with Genmab working on TV, and we continue to look forward to presenting more and more data.
Thank you, sir. We now have no further questions in the queue.
Okay. Thank you, operator and thanks everybody for joining us today. Have a good night.
Thank you, ladies and gentlemen. This concludes today's teleconference. You may now disconnect and please, enjoy the rest of your evening.